Therapeutic potential of α2 adrenoceptor antagonism for antipsychotic-induced extrapyramidal motor disorders

Neuroscience Letters

Volumn 454, Issue 2, 2009, Pages 143-147

  Imaki, Junta ^a   Mae, Yukari ^a   Shimizu, Saki ^a   Ohno, Yukihiro ^a  

^a OSAKA MEDICAL COLLEGE   (Japan)

Author keywords

2A receptor; 2C receptor; Antipsychotics; BRL 44408; Extrapyramidal motor disorders; JP 1302

Indexed keywords

2 (1 METHYL 2 ISOINDOLINYLMETHYL) 2 IMIDAZOLINE; ALPHA 2 ADRENERGIC RECEPTOR BLOCKING AGENT; HALOPERIDOL; JP 1302; UNCLASSIFIED DRUG; YOHIMBINE; ACRIDINE DERIVATIVE; ALPHA 2 ADRENERGIC RECEPTOR; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; IMIDAZOLE DERIVATIVE; ISOINDOLE DERIVATIVE; JP-1302; NEUROLEPTIC AGENT; PIPERAZINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRADYKINESIA; CATALEPSY; CONTROLLED STUDY; EXTRAPYRAMIDAL SYNDROME; MALE; MOUSE; NONHUMAN; OPEN FIELD TEST; PRIORITY JOURNAL; ANALYSIS OF VARIANCE; ANIMAL; CHEMICALLY INDUCED DISORDER; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; HYPOKINESIA; MOTOR ACTIVITY;

ACRIDINES; ADRENERGIC ALPHA-ANTAGONISTS; ANALYSIS OF VARIANCE; ANIMALS; ANTIPSYCHOTIC AGENTS; CATALEPSY; DOSE-RESPONSE RELATIONSHIP, DRUG; HALOPERIDOL; HYPOKINESIA; IMIDAZOLES; ISOINDOLES; MALE; MICE; MOTOR ACTIVITY; PIPERAZINES; RECEPTORS, ADRENERGIC, ALPHA-2; YOHIMBINE;

EID: 62949115816     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neulet.2009.03.001     Document Type: Article

References (29)

1. 2A-adrenergic receptor knockout mice. Mol. Pharmacol. 56 (1999) 154-161
2. Barnes C.D. The basal ganglia in extrapyramidal dysfunction. Brain Res. Bull. 11 (1983) 271-275
3. Drevets W.C., Price J.L., and Furey M.L. Brain structure and functional abnormalities in mood disorders: implication for neurocircuity models of depression. Brain Struct. Funct. 213 (2008) 93-118
4. 2-adrenoceptor antagonist idazoxan reverses catalepsy induced by haloperidol in rats independent of striatal dopamine release: role of serotonergic mechanisms. Neuropsychopharmacology 28 (2003) 872-879
5. Ishiyama T., Tokuda K., Ishibashi T., Ito A., Toma S., and Ohno Y. Lurasidone (SM-13496), a novel atypical antipsychotic drug, reverses MK-801-induced impairment of learning and memory in the rat passive-avoidance test. Eur. J. Pharmacol. 572 (2007) 160-170
6. 2-adrenoceptor antagonism in the anti-cataleptic properties of the atypical neuroleptic agent, clozapine, in the rat. Br. J. Pharmacol. 124 (1998) 1550-1556
7. 2C-Adrenoceptor blockade by clozapine and other antipsychotic drugs. Eur. J. Pharmacol. 462 (2003) 33-40
8. 1A receptor activation. Psychopharmacology 177 (2005) 373-380
9. 2-Adrenoceptor subtypes-unexpected functions for receptors and ligands derived from gene-targeted mouse models. Neurochem. Int. 51 (2007) 277-281
10. 2A-adrenergic receptor knock-out mice. Neuroscience 113 (2002) 289-299
11. 2A-adrenoceptor subtype. Neuropharmacology 44 (2003) 882-892
12. 2-adrenergic receptor subtypes b and c. Science 273 (1996) 803-805
13. McNaughton N. Cognitive dysfunction resulting from hippocampal hyperactivity-a possible cause of anxiety disorder?. Pharmacol. Biochem. Behav. 56 (1997) 603-611
14. Meltzer H.Y., Li Z., and Ichikawa J. Serotonin receptors: their key role in drugs to treat schizophrenia. Prog. Neuro-Psychopharmacol. Biol. Psychiat. 27 (2003) 1159-1172
15. 2 receptor antagonist, using the mouse pole test. Pharmacol. Biochem. Behav. 49 (1994) 19-23
16. 1A agonists using the mouse pole test. Prog. Neuro-Psychopharmacol. Biol. Psychiat. 32 (2008) 1302-1307
17. Ohno Y., Shimizu S., Imaki J., Ishihara S., Sofue N., Sasa M., and Kawai Y. Anticataleptic 8-OH-DPAT preferentially counteracts with haloperidol-induced Fos expression in the dorsolateral striatum and the core region of the nucleus accumbens. Neuropharmacology 55 (2008) 717-723
18. Racagni G., Canonico P.L., Ravizza L., Pani L., and Amore M. Consensus on the use of substituted benzamides in psychiatric patients. Neuropsychobiology 50 (2004) 134-143
19. 2C-adrenergic receptor-like immunoreactivity in the rat central nervous system. J. Comp. Neurol. 372 (1996) 135-165
20. 2-adrenoceptor subtypes. Annu. Rev. Pharmacol. Toxicol. 33 (1993) 243-279
21. 2C-receptors modulate the acoustic startle reflex, prepulse inhibition, and aggression in mice. J. Neurosci. 18 (1998) 3035-3042
22. 2-adrenoceptor subtype c in mice affects the development of behavioral despair and stress-induced increases in plasma corticosterone levels. Mol. Psychiat. 4 (1999) 443-452
23. 2C-adrenoceptor antagonist JP-1302. Br. J. Pharmacol. 150 (2007) 391-402
24. Samii A., Nutt J.G., and Ransom B. Parkinson's disease. Lancet 363 (2004) 1783-1793
25. 2-adrenergic receptor subtype gene expression in rat brain. Brain. Res. Mol. Brain. Res. 21 (1994) 133-149
26. 2C-adrenoceptor as a neuropsychiatric drug target studies in transgenic mouse models. Life Sci. 68 (2001) 2277-2285
27. 2A-adrenergic receptor plays a protective role in mouse behavioral models of depression and anxiety. J. Neurosci. 21 (2001) 4875-4882
28. 2C-adrenoceptor-deficient mice. Neunyn-Schmiedeberg's Arch. Pharmacol. 364 (2001) 117-130
29. 2C adrenoceptors inhibit adenylate cyclase in mouse striatum: Potential activation by dopamine. J. Pharmacol. Exp. Ther. 289 (1999) 1286-1292